Jeffrey S. Andrews

Sr. Director, Global Brand Development Leader - Insulin Connected Care, Eli Lilly and Company

Jeff Andrews began his career in pharmaceuticals when he joined Eli Lilly and Company in 2001. In his current position as Global Brand Development Leader – Connected Care, Jeff leads an integrated team responsible for the development of connected insulin delivery devices and mobile medical applications that are intended to make insulin therapy management less burdensome for our customers and ultimately to improve outcomes for people with diabetes.

His past positions with Lilly have all been focused on diabetes and include new product planning, global marketing, market research, and US affiliate commercialization. Jeff’s experience base spans from working on development and commercialization efforts for pre-submission products to execution with in-market brands. Throughout these experiences, Jeff has also worked on several pharmaceutical and biotechnology partnerships across both molecules and delivery devices. He is passionate about improving the lives of people with diabetes, and those that help care for them, through better products and services.

Jeff graduated from Bradley University with a B.S. in business management, and received an M.B.A. from Kenan-Flagler Business School at the University of North Carolina at Chapel Hill. He currently resides with his wife, Sarah, and son, Aiden, in Cambridge, MA.


Dr. Kevin Biese

UNC Emergency Medicine Vice Chair and Co-Chief Division Getriatric Emergency Medicine, UNC Health Care; Consultant, West Health

Dr. Biese serves as an Associate Professor of Emergency Medicine (EM) and Internal Medicine, Vice-Chair of Academic Affairs, and Co-Director of the Division of Geriatrics Emergency Medicine at the University of North Carolina (UNC) at Chapel Hill School of Medicine as well as a consultant with West Health.

With the support of the John A. Hartford and West Health Foundations, and alongside Dr. Ula Hwang, he serves as Co- PI of the national Geriatric Emergency Department Collaborative. He chairs the first Board of Governors for the ACEP Geriatric Emergency Department Accreditation Program. Finally, he has helped develop an innovative model of care utilizing telemedicine to facilitate care of skilled nursing facility residents at SNFs.


Paul Boyer

Former CFO, Humacyte, Inc.

Mr. Boyer has been a senior executive and entrepreneur at companies such as RivalHealth, Agion Technologies, Solicore, SwitchPoint Networks and BriteSmile. He has spent the past 25 years as a CFO and/or COO of private and public companies from start-up to $700M in revenues.

Boyer holds a bachelor’s degree in accounting from San Diego Mesa College. He lives in Raleigh, North Carolina, United States.


Dr. Sam Bozzette, MD, PhD

Vice-President and Chief Scientist, Premier Applied Sciences

Samuel Bozzette, MD, PhD is an internationally recognized researcher and physician executive. He currently Vice-President and Chief Scientist at Premier Applied Sciences the research arm of Premier, a leading healthcare company.

Previously, he served as Vice-President, Medical Affairs-Americas and head of post-market research at bioMerieux, a diagnostics company, and as a Physician Executive at Cerner, a health information technology company.

Prior to that, he was Senior Natural Scientist at the RAND Corporation and Professor of Medicine and of International Relations at the University of California San Diego. There he led a program of clinical, services, economic, outcomes, and policy investigations resulting in over 180 publications, including over a dozen in the New England Journal of Medicine. Dr Bozzette holds a B.S. from Georgetown University, an M.D. from the University of Rochester, and a Ph.D. in Policy Studies with Distinction in Economics and Quantitative Methods from the RAND Pardee Graduate School. He is certified in Internal Medicine and Infectious Diseases. He is a fellow of the American College of Physicians and the Infectious Diseases Society of America, and an elected member of American Society for Clinical Investigation, the Association of American Physicians, and the Pacific Council on International Policy.


Sean Callinicos

SVP, Global Government Relations & Public Policy, Cardinal Health

Sean leads the global government relations and public policy function at Cardinal Health, a Fortune 15 company ($137B in 2017 revenue). Previously, from 2010-15, Sean was a senior government relations representative for the French biopharmaceutical company Sanofi.

From 2004-10, Sean ran the government relations office for Sanofi’s vaccine division, Sanofi Pasteur, the world’s largest human vaccine company. Previously, Sean led the global government relations and policy function for a high-technology company, worked for the U.S. Senate as both Committee and personal staff, and practiced corporate law. Sean earned a B.A., Phi Beta Kappa, from the University of North Carolina-Chapel Hill and a J.D., High Honors, from the Duke University School of Law.


Scott Carberry

Product Manager, Dermatology HCP Team, The Janssen Pharmaceutical Companies of Johnson & Johnson

Dr. Theresa Cullen, M.D., M.S., RADM (Ret.)

US Public Health Service; Visiting Associate Professor of Family Medicine at Indiana University School of Medicine

Theresa Cullen is a Visiting Associate Professor of Family Medicine at the Indiana University School of Medicine. She concurrently serves as the Associate Director of Global Health Informatics at the Regenstrief Institute. From 2012 - 2015, she served as the Chief Medical Information Officer at the Veterans Health Administration, covering operational areas such as human factors, knowledge based systems, applied informatics services, personal health record, barcode, and other programs.

From 2006 – 2011, Dr. Cullen served as the Chief Information Officer for the Indian Health Service. She earned her M.S. in Administrative Medicine from the University of Wisconsin-Madison and her M.D. at the University of Arizona College of Medicine, where she also served her residency in Family Medicine. She is board certified in Family Medicine and Clinical Informatics.


Shawn Davis, PharmD, MBA

Sr. Director, Pharma Strategy & Contracting, Express Scripts

Shawn helps Express Scripts’ clients improve patient’s health while reducing costs by developing solutions to deliver complex, life-saving medications at sustainable prices.

His responsibilities include:

  • Develop strategies to optimally place manufacturer products onto Express Scripts’ standard and custom formularies
  • Architecting innovative solutions including the Inflammatory Conditions Care Value Program and Oncology Care Value Program
  • Leading the Express Scripts’ biosimilar strategy


Shawn chaired the Value Assessment Committee for 2016-2017, and delivered more than $2 billion incremental rebate dollars to plan sponsors during his tenure. His previous experience includes integrating and expanding Express Scripts’ Utilization Management (Step Therapy, Prior Authorization and Drug Quantity Management) portfolio and developing the company’s compound management program that saved clients more than $2.5 billion in pharmacy costs.

Shawn earned his Doctor of Pharmacy from The Ohio State University and his Master’s in Business Administration at Kenan-Flagler Business School at The University of North Carolina at Chapel Hill.


Kaitlyn Edsall

Principal, Life Sciences Practice, Charles River Associates

Kaitlyn Edsall is a Principal in the Life Sciences Practice of CRA. She is an expert in customer insights and data strategy with a specialty in life sciences and healthcare. Ms. Edsall oversees market research and strategy projects from early pipeline opportunity assessments and forecasts to commercial portfolio management strategies.

She specializes in immunology, rare disease and women’s health. In her previous roles, Ms. Edsall has specialized in qualitative and quantitative research, particularly patient and HCP segmentation and targeting, competitive brand positioning, strategic messaging, and corporate and brand reputation tracking. She has experience leading varied strategic market research projects to inform marketing and communications campaigns with clients from various global health sectors. Prior to her role at CRA, Ms. Edsall was a manager at C1 Consulting and former head of insights for Health and Wellness accounts at Edelman NY.

Ms. Esdall received her BA from Georgetown University and her MBA from the University of Cambridge.


Steve Galatis

Director, Strategic Options and Assessment at BMS

Steve Galatis Leads BMS’s Strategic Options and Assessment (SO&A) team. SO&A is part of the R&D tower of our Business Analytics and Insights (BIA) division. SO&A acts as strategy consultants to development teams, providing a value lens on development decisions. SO&A also acts as an integrator of BIA’s analytics for BMS’s development teams.

Prior to joining BMS in 2010, his career was spent as an outside consultant. In those roles, he has worked in a number of industries and in a variety of different situations: product development, R&D portfolio, business unit, and company-level business portfolio. Most of his strategy work has used either decision-analytic or game-theoretic approaches.

Steve has a BA in Economics from Michigan State, and a Masters in Economics from Stanford.


Hilary Gentile

Chief Strategy Officer, McCann Health North America

As Chief Strategy Officer, McCann Health North America, Hilary is responsible for leading strategy teams and driving integration across all agencies in North America. Partnering with US-based and global clients, Hilary marries creative and critical thinking to solve high-level problems for her Fortune-500 clients, from portfolio strategy, to system architecture, to forward planning, to establishing a brand or company’s meaningful role.

Hilary builds engaging solutions for healthcare providers, patients, and payers, as well as manufacturers, health systems, pharmacies, and NGOs. As a testament to this multi-disciplinary excellence, Hilary was inducted into the 2017 MM&M Hall of Femme.

Among her major accomplishments is the formalizing of McCann Health’s strategic-planning process, Truth 2 Meaning (T2M), which has been implemented around the world. This unified process has been instrumental in driving business development and capability expansion. Additionally, T2M has allowed Hilary to establish an agile and connected team, who can integrate on-demand to solve diverse client issues, regardless of vertical. Through co-creation, challenge sessions, live panel discussions, projective simulations, and ecosystem models, Hilary leads her team to diagnose business issues and unearth new opportunities for her clients. Hilary has also created the proprietary strategic tool known as Future-Scape, which helps in analyzing future-forward trends that will take place in the next 2-3 years and what an organization needs to do today to prepare for these changes. Continuing to always look to the future, Hilary has brought together digital experts across McCann Health in anticipation of the launch of the McCann Health Idea Accelerator in 2019. In preparation for a modern marketing strategy, Hilary has partnered with Estonian innovation leaders, automotive customer experience architects, and IBM Watson data scientists.

Guided by cultural and psychological truths, which influence human behavior and actions, Hilary and her team have partnered with major brands to uncover customer insights for competitive differentiation. In pursuit of uncovering these truths, Hilary regularly conducts Think Tank and Hack-A-Thon brainstorms, with her direct teams and with clients. Recently, Hilary led the launch of McCann’s Truth About Doctors study, which mapped the future of healthcare from the provider’s perspective by interviewing 2,000 doctors in 17 markets from the U.S. to the Philippines. Her work on Truth About Doctors has opened the door for McCann Health to partner with top-tech companies and start-ups to solve the most pressing issues of the new healthcare ecosystem and improve the doctor-patient relationship. This work led to several keynote addresses to clients, including Bristol Myers-Squibb, Bayer, Janssen, GSK, Lilly, and Novartis, as well as at institutions, such as the University of North Carolina and International Society for Medical Publication Professionals (ISMPP).

This year she and her team have established the Social Science practice which unlocks the covert drivers of human behavior. This includes tools such as ARULE™ (our proprietary health literacy and behavior change framework, trademarked at the McCann Worldgroup level, and validated in partnership with Columbia University’s Mailman School of Public Health) and building McCann Health behavioral economics and choice architecture constructs. Most recently, Hilary assembled the inaugural meeting of the Global Strategy Community for McCann Health, bringing together the agency’s leading strategists from across the world to help solve client challenges and learn how to work together best.

A Smith College alum, Hilary studied sociology, biology, and histology. After training at the University of Pennsylvania Perelman School of Medicine, she began her career in clinical research before transitioning to pharmaceutical marketing and advertising. Within McCann Health’s global network, Hilary is creating a coalition of Women in Technology, however, outside of McCann Health’s walls, she continues to share her craft by coordinating STEM programs for young women in the NY/NJ metropolitan area. Hilary lives in New Jersey with her husband and two children.


Kyle Gibler, MD, MBA

Associate Partner, McKinsey & Company

Kyle Gibler is an Associate Partner in McKinsey & Company’s Charlotte office. He is a physician with significant healthcare industry consulting experience, primarily in strategy and clinical operations in for-profit and non-profit health systems.

He specializes in supporting hospitals and physician groups in reducing clinical and operational variability to support transitions to value-based care payment models. Kyle co-leads McKinsey’s Value-Based Care practice and serves on internal committees on non-acute care and technology-enabled care delivery disruption.

Kyle graduated with his MD from Duke University School of Medicine as a member of the Alpha Omega Alpha Honor Society, as well as an MBA from University of North Carolina Kenan-Flagler Business School as a Richard Jenrette Scholar and Falls Prize recipient. Kyle graduated magna cum laude with an AB in Economics & Health Policy from Harvard University, where he was a John Harvard Scholar.


Dr. Mark Gwynne, DO

Interim President, Executive Medical Director, UNC Health Alliance

Dr. Gwynne currently serves as the Interim President, Executive Medical Director of UNC Health Alliance, UNC’s Clinically Integrated Network and UNC Senior Alliance, UNC’s Next Generation ACO. Dr. Gwynne completed his residency and fellowship training in family medicine and faculty development at UNC Chapel Hill, and has served on faculty as an Associate Professor of Family Medicine in the UNC School of Medicine for the past 15 years where he continues to provide direct patient care in both the outpatient and inpatient settings.

He has served in many local, regional and national administrative roles with a focus on healthcare system transformation, care delivery redesign to meet population health needs, and Value based care delivery and payment models. Dr. Gwynne has led regional collaboratives to design, implement and scale interdisciplinary population health initiatives throughout his career and has published significantly on care redesign. Currently, Dr. Gwynne is focused on leading UNC and North Carolinas transition to Value and enhancing payor-provider partnerships to achieve that goal.


Richard Hallquist

Associate Director of Global Services, IQVIA Analytics Center of Excellence (ACOE)

Richard Hallquist is an Associate Director of Global Services within IQVIA’s Analytics Center of Excellence (ACOE) and leads the RWE studies group within the ACOE. The ACOE uses real-world data and advanced analytics to find better ways to help sponsor’s plan and execute studies.

Richard has been with IQVIA since 2017. Prior to IQVIA, Richard spent 4 years at GlaxoSmithKline in a leadership rotational program (Esprit) with roles in both commercial and R&D. He additionally has 10 years’ experience working in the field of analytics including 6 years at the SAS Institute. Richard holds an M.B.A. from UNC Kenan-Flagler Business School, an M.A. in Mathematics from the University of Maryland – College Park, and a B.A. in Mathematics from Colby College.


Hank Head

VP of Clinical Technology, OptumHealth

Hank Head has held top strategic product leadership and strategic planning positions at numerous clinical decision support / medical informatics companies. He has designed and delivered clinical decision support (CDS) and advanced electronic health records (EMR/EHR) systems for governments, NGO’s, diagnostic, insurance and other private sector companies such as Optum, McKesson, Medscape, LabTracker, Virco Diagnostics, and TherapyEdge.

His most recent projects involved creating highly structured guideline content for the national comprehensive cancer network (NCCN) which helps physicians and payers more effectively use guideline evidence at the point of care. He has also created systems that use genetic data to optimize treatment options and has authored four unique graph based decision authoring systems for the creation of high-quality portable clinical content.

Prior to joining Optum, Hank spent over 5 years as an IT Executive leading clinical reasoning, value based care solutions and team based care products at McKesson. The value based care treatment recommendation options moved clinicians from below 50% compliance with evidence to over 87% compliant saving 100’s of millions in the cost of chemotherapy across 400K decisions.
Hank graduated from the University of Southern California Veterbi School of Engineering and resides in Eflan, NC with his three children.


Jeanne Hecht

CEO and Founder, JTH Consulting, LLC

Jeanne Taylor Hecht is a global Business Executive and Board Member with deep experience leading successful teams across mature and emerging markets within the product development, pharma services and life sciences space.

As Chief Executive Officer and Founder of JTH consulting LLC, Jeanne is responsible for the growth of a consulting practice in the Life Sciences arena focused on supporting companies with their sales, marketing and market growth strategies as well as advisory and board work. Prior to launching her company, Jeanne was a member of the Board and Chief Operating Officer of Median Technologies, where she was responsible for leading, implementing and driving the company’s global strategy. The company develops, and markets medical software used for the management and tracking of cancerous lesions diagnosed by imaging; its new product development efforts focus on medical devices for the diagnosis and support of NASH/NAFLD and in oncology indications. In 2017, she returned the company to positive growth. She launched three new products; scaled the organization across the U.S., Europe and Asia; and established the LLC in Hong Kong and WOFE in China.

Concurrently, Jeanne is Chief Executive Officer and Founding Owner of Cassidy Investment Partners, LLC, which invests in real estate and small start-up companies. She also is an active Board Member of Ora Clinical, and is an Advisory Board Member for the University of North Carolina Chapel Hill Kenan-Flagler’s Business School Industry Health Council as well as is an active lecturer at the business school.

Earlier in her career, Jeanne was Senior Vice President of Global Head of Site and Patient Networks for Iqvia (formerly Quintiles IMS Holdings, Inc.), an international company that provides biopharmaceutical development and commercial outsourcing services. With P&L responsibility, she oversaw a team spanning the U.S., Europe, the Middle East, Africa and Asia. She was a Member of the Quintiles Executive Committee, the top 33 individuals in the organization, and President of the Quintiles WIN (Women in Networking) group.

As Senior Vice President, Global Head of Sales ¬Product Development, for Quintiles, Inc., Jeanne led a team of more than 250 sales experts across all global markets and led the sales strategy that supported the Quintiles entry into the public market (IPO). Prior to this, she held a number of leadership positions of increasing responsibility with the company. She also was Vice President of Marketing & Sales for Decision Biomarkers, Inc.

As Regulatory Affairs Officer for the UNC Oncology Protocol Office, Jeanne was responsible for the management and oversight of clinical research being conducted. She served as a member of the Oncology Protocol Review Committee; was the primary liaison responsible for all correspondence and submissions to the Food and Drug Administration; and developed Standard Operating Procedures for the management and oversight of 30 Cancer Center Affiliate sites. She entered the Office as Senior Regulatory Associate after having been Records Management Administrator for Parke-Davis. She began her career as a teacher at ASSETS School for the Gifted/Dyslexic Student in Honolulu, HI.

Throughout her career, Jeanne has been a sought-after speaker and presenter, and author on several topics, including clinical care and women in health care. She has addressed Congress, spoken before the British Prime Minister, published a number of articles and was the invited speaker at several investment conferences.

Jeanne volunteers with Senior PharmAssist, a nonprofit group that provides medication access and medication therapy management to seniors in North Carolina. She further volunteers with Kids=Play, a nonprofit group building playgrounds for children with disabilities in Southern Virginia, and with Ronald McDonald House. She holds a Bachelor of Science from the University of Michigan and a Master of Business Administration from the university’s Ross School of Business. She earned a Certificate of Project Management from the Project Management Institute.

In her free time Jeanne enjoys spending time with her husband, playing with their dog, Scuba diving (she is a technical diver), playing tennis, reading, cooking and bird watching.


Kirstin Heinrich

Senior Manager, Vaccines Global - Health Economics and Outcomes Research, Pfizer

Kirstin Heinrich is an emerging leader welcoming the challenge of improving global health outcomes by delivering meaningful innovations through the private sector. In her current position in Health Economics & Outcomes Research (HEOR) for Pfizer, Inc., a global pharmaceutical company, she leads the development and execution of the global HEOR strategy towards optimal market access for Pfizer’s late-stage pipeline C. difficile vaccine.

This includes generating and communicating robust and compelling evidence of value to ensure the right people will have access to the vaccine at the right time, the right place and at the right price. Kirstin began her career in HEOR at Becton, Dickinson and Co. (BD), a global medical technology company, in the Diabetes Care and Biosciences business units. She holds a Master’s degree in public health epidemiology with a Certificate in comparative effectiveness and outcomes research from Columbia University in New York City, where she is also a Macy Scholar. Kirstin also holds a Certificate in health economics from the University of Chicago and a Bachelor of Science (BS) in Public Health from Tulane University in New Orleans, Louisiana, graduating magna cum laude with Departmental Honors. Kirstin is currently pursuing an MBA from UNC Kenan-Flagler School of Business through the MBA@UNC program.


Dr. Ed Hunsinger, MD

Senior Medical Executive, CIGNA

Dr. Hunsinger has served as Cigna’s Senior Medical Executive in various roles since 2007. Currently he is responsible for medical leadership in the Carolinas. On a daily basis, he works with employer groups and healthcare systems, forming collaborative care partnerships, which now cover over 200,000 individuals.

Dr. Hunsinger received his BS and MD degrees from the University of Florida where he also completed his Family Practice residency training. Dr. Hunsinger was a recipient of the National Mead Johnson Award and practiced full time as a family physician for 12 years, during which time he was instrumental in developing one of the first managed care programs in Florida.

During the 1990’s Dr. Hunsinger was the founding CEO of the community-based primary care network for Wake Forest University in Winston Salem, NC.

Dr. Hunsinger is married, has two grown children, 3 adorable grandchildren and enjoys biking and paragliding.


Paul Jaglowski

Co-Founder and CEO, Feedtrail, lnc.

Paul is the Co-Founder and CEO of Feedtrail, a healthcare IT company that is changing the way healthcare organizations learn from their patients in real time. Rather than rely on outdated and after-the-fact surveying, Feedtrail’s web-based platform allows patients to share candid feedback while still receiving care so that on-duty staff can identify specific opportunities for organizational improvement and recover all service issues prior to discharge. It has never been easier for healthcare teams to ensure every patient receives the care he or she deserves.

In 2018, Paul was named as one of the 30 Rising Customer Experience Super Stars under 30 (CX 30 Under 30) by CX Network, which is the leading online resource for senior customer experience, service, insight, digital and marketing decision makers. Prior to co-founding Feedtrail, Paul worked as a management and strategy consultant for Booz Allen Hamilton in Washington, D.C. and in an operations role for fintech startup OnDeck Capital as it was preparing for IPO.


Brett Kenefick

President, VaxCare

Howard Kern

President and CEO, Sentara Healthcare

Howard Kern is President and Chief Executive Officer of Sentara Healthcare, a not-for-profit integrated health system located in Virginia with net revenues of $6.3 billion. Sentara is comprised of 12 acute care hospitals, 7 nursing and rehabilitation centers and one assisted living community in Virginia and northeastern North Carolina, with approximately 1,000 providers in its four medical groups.

Sentara also operates a health plan with 500,000 covered lives in Virginia, North Carolina and Ohio. Sentara has continually ranked as one of the most integrated health care networks in the United States by Modern Healthcare magazine, and is the only health care system in the nation to be named in the top 10 continuously since the survey began.

Sentara Healthcare was named to the Forbes 2018 America’s Best Employers list (5,000+ employees), ranking #177 out of 500 companies in the Best Large Employers category. Sentara was nationally recognized as a Top 15 Health System in 2018 by IBM Watson Health (formerly Truven Analytics) in the large system category. In addition, U.S. News & World Report recently ranked five of Sentara’s hospitals in their 2018 “Best Hospitals” Edition.

Mr. Kern was recognized as #58 on Modern Healthcare’s 100 Most Influential People in Healthcare in 2018. His executive management experience includes 38 years in hospital, managed health insurance, ambulatory services and healthcare finance. Mr. Kern obtained his Masters in Health Administration from the Medical College of Virginia, and is on the faculty as a lecturer in the School of Health Administration. He is a Fellow in the American College of Healthcare Executives and also completed the CEO Program for Health Care Leadership at the Leonard Davis Institute for Health Economics at the Wharton School, University of Pennsylvania.

He serves on numerous corporate and community boards including E3 (Elevate Early Education), Future Hampton Roads, Hampton Roads Business Roundtable, Hampton Roads Economic Development Alliance (HREDA), MDLive, ReInvent Hampton Roads, Virginia Biosciences Health Research Corporation, the Virginia Symphony Orchestra, Virginia Wesleyan University and Vizient.


Susanne Laningham

Executive Director of Global Value, Access & Policy, Amgen, Inc.

Susanne Laningham is an Executive Director of Global Value, Access & Policy at Amgen, Inc. She has an established track record of developing and implementing market access and pricing strategies for pipeline and launch assets, including alignment with clinical trial strategy, evidence generation planning, development of launch pricing and reimbursement strategies, and strategies to negotiate with payers and HTA authorities.

Susanne is currently the head of Value & Access for Amgen’s Intercontinental region, responsible for directing activities related to obtaining market access from payers in Canada, Latin America, Turkey, Middle East, and Africa. Prior to her current position, Susanne was the Therapeutic Area head of Cardiovascular & Neuroscience in Global Pricing & Market Access leading a team responsible for developing global strategies in health economics, pricing, access planning and health policy to demonstrate the value of and secure access to Amgen’s innovative medicines, including Repatha® (evolocumab).

Before joining Amgen in 2006, Susanne consulted biopharmaceutical clients as a Director of Managed Markets at Campbell Alliance. In this role Susanne helped clients develop and execute launch strategies in several disease categories including cardiovascular disease, metabolic disease, immunology & inflammation, and urology.

Susanne received her undergraduate degree in chemistry from Duke University before completing a Masters in chemistry from the University of Virginia and an MBA from the University of North Carolina at Chapel Hill.


Edward Lloyd-Evans

Global Health Consultant, ELE Consulting LLC

Edward Lloyd-Evans is a Global Health and Development consultant. He works in a diverse range of development efforts aimed at finding creative new, high impact and sustainable solutions, “so others shall live”.

Edward’s work involves collaborating with governments, stakeholders and partners in effectively sourcing, designing, developing and implementing impactful healthcare plans for developing countries.

Prior to his current consulting practice, he served as Senior Program Manager of Gates CEO Global Health Roundtable, a partnership between the Bill & Melinda Gates Foundation (BMGF) and 17 multinational Biopharmaceutical companies to address challenging global health needs, primarily around the advancement of: Neglected tropical diseases; Tuberculosis; Access and Affordability of Medicines; Supply Chain, etc. Edward also led the Partner Relationship Management Program while at the Gates Foundation between 2013 to 2015, which focused on strengthening relations between BMGF and its critical strategic partners in four key sectors: multilaterals, corporate, government, academia and NGOs. He has over 24 years combined experience working with Gates Foundation, World Health Organization, private sector (including General Electric) and in management consulting with executive leadership teams for large global corporations such as Wells Fargo and Bank of America.

A United States citizen and native of The Gambia. He holds an MBA from Kenan Flagler Business School at the University of North Carolina at Chapel Hill and a Bachelors in Finance from Providence College, Rhode Island. Edward advises and guest lectures on topics in Global Health at Kenan Flagler Business School, University of North Carolina at Chapel Hill.


Steve Malik

Executive Chairman, Medfusion

Larry Mandelkehr

Executive Director of Hospital Quality and Innovation, UNC Health Care System

Larry Mandelkehr is Executive Director of Hospital Quality and Innovation for the University of North Carolina Health Care System. In this role, he leads the development and execution of the system-wide hospital-focused strategic quality plan and leads relationship building initiatives and quality improvement opportunity assessment with administrative and clinical leadership at all UNC hospitals.

Larry leads the process to establish hospital quality and safety organizational quality goals and provides information to senior management. He monitors key quality and safety measures in order to improve processes and outcomes with focus on patient care and performance in public and private incentive and reporting programs. Larry collaborates with senior management to develop and implement innovative improvement models geared towards capitalizing on a variety of the UNC Health Care’s value based strengths to improve care, cost, experience and value.

Prior to joining UNC Health Care, Larry worked in engineering and marketing management, developing instrumentation and supervisory control and decision support systems for the oil and gas industry.

In his ‘spare time’ for the past 20 years, Larry is an Adjunct Associate Professor and teaches quality and information management at UNC’s Gillings School of Global Public Health, and teaches an Excel “bootcamp” at UNC’s Kenan-Flagler Business School. He is also an Adjunct Assistant Professor, guest speaker and preceptor at the UNC School of Nursing.

Larry has a MBA from UNC’s Kenan-Flagler Business School, Bachelors and Masters Degree in Electrical Engineering from Rensselaer Polytechnic Institute and is a Certified Professional in Healthcare Quality.


Dr. Peter Marks, MD, PhD

Director of the Center for Biologics Evaluation and Research, U.S. FDA

The Center for Biologics Evaluation and Research is responsible for assuring the safety and effectiveness of biological products, including vaccines, allergenic products, blood and blood products, and cellular, tissue, and gene therapies. Dr. Marks and center staff are committed to facilitating the development of biological products and providing oversight throughout the product life cycle.

Dr. Peter Marks received his graduate degree in cell and molecular biology and his medical degree at New York University. Following this, he completed an Internal Medicine residency and Hematology/Medical Oncology fellowship at Brigham and Women’s Hospital in Boston, where he subsequently joined the attending staff as a clinician-scientist and eventually served as Clinical Director of Hematology.

He then moved on to work for several years in the pharmaceutical industry on the clinical development of hematology and oncology products prior to returning to academic medicine at Yale University where he led the Adult Leukemia Service and served as Chief Clinical Officer of Smilow Cancer Hospital. He joined the FDA in 2012 as Deputy Center Director for CBER and became Center Director in 2016. Dr. Marks is board certified in internal medicine, hematology and medical oncology, and is a Fellow of the American College of Physician.


Dana G. Mead, Jr.

President and CEO, Beaver-Visitec International

Dana Mead brings to BVI over 30 years of global medical device experience as a general manager, venture investor and sales and marketing executive. Before assuming his current role, Dana was a Strategic Advisor and Partner in the Life Science Practice of Kleiner Perkins Caufield & Byers (KPCB), a leading venture capital firm, where he helped identify and grow early-stage healthcare companies.

Prior to KPCB, he held a series of senior-level positions at Guidant Corp., that included; President Vascular Intervention (VI), VP Corporate Relations, President Asia Pacific Operations (Based in Tokyo), General Manager, Stent Business Unit (VI) and General Manager, Origin. Earlier in his career, Dana served in sales and marketing roles in the Ophthalmic Groups of Allergan and Johnson and Johnson. He currently serves on the Board of Directors of Inspire Medical (NYSE:INSP), Intersect ENT (NASDAQ:XENT) and Pulmonx. Mr. Mead has served on the BOD’s of over 20 organizations including: Teladoc (NYSE:TDOC), Spinal Modulation (Acquired by St. Jude), Corventis (Acquired by Medtronic), The California Healthcare Institute (CHI) and Lucille Packard Children’s Hospital (LPCH) at Stanford.

Dana has a Bachelor’s Degree from Lafayette College and a Masters of Business Administration (MBA) from the University of Southern California.


Dr. Brian Miller, MD, MBA, MPH

Adjunct Professor, UNC Kenan-Flagler School of Business; Georgetown University

Professor Miller teaches insurance design in the M.B.A. program at the Kenan-Flagler Business School. He is completing a second residency in Internal Medicine at Georgetown University and serves as a consultant to the FTC Bureau of Consumer Protection.

Dr. Miller previously served as a medical officer and reviewer in the Office of New Drugs at the Center for Drug Evaluation and Research at the FDA where he was one of two physicians who reviewed and approved valbenazine, a first-in class new molecular entity for tardive dyskinesia. Prior to his FDA tenure, Dr. Miller completed a Public Health Residency jointly sponsored by Johns Hopkins University and the federal government, comprised of a federal regulatory rotational program with postings at CMS, FTC, FCC, and FDA and clinical practice at Johns Hopkins Community Physicians. As a Special Advisor at the FTC, Dr. Miller served as an in-house physician expert assisting in merger review & enforcement in health systems, PBMs, and pharmaceuticals, including the FTC’s successful action blocking the $7 billion Advocate-NorthShore merger.

Prior to the FTC, Dr. Miller was a Fellow at the CMS Innovation Center, where he co-managed the ACO Investment Model, a $114 million project focused on ACOs in rural & underserved areas. He has published in The New England Journal of Medicine, The American Journal of Managed Care, and Health Affairs Blog. He is board-certified and licensed to practice medicine in Washington, DC.

Dr. Miller received his M.D. from the Feinberg School of Medicine at Northwestern University, his M.B.A. from the Kenan-Flagler School of Business at the University of North Carolina at Chapel Hill, and his M.P.H. from the Bloomberg School of Public Health at the Johns Hopkins University. He lives in Washington, D.C.


Joe Modisett

Head of U.S. Healthcare Investment Banking, Morgan Stanley

Joe leads the U.S. Healthcare Group within Morgan Stanley’s Investment Banking Division. Joe joined Morgan Stanley in 1998 in New York. In addition to New York, Joe spent time in Menlo Park, CA in 1999 and in London from 2004-2006.

Over the past 10 years, Joe has advised on over $300Bn of M&A activity within healthcare across buy-sides, sell-sides and portfolio restructurings including Abbott’s acquisition of St. Jude, AbbVie’s acquisition of Pharmacyclics, Hospira’s sale to Pfizer and Merck’s sale of its OTC business to Bayer. In addition to M&A, Mr. Modisett has led numerous jumbo IPO’s including Elanco, Catalent, Zoetis, Talecris and Mead Johnson. Joe also has significant cross-border and emerging markets expertise having led the largest life science acquisitions inbound to India (Abbott/Piramal) and outbound from China (Creat/Biotest).

Joe graduated with highest honors with a BS in Business Administration/Finance from the University of North Carolina at Chapel Hill.


Art Pappas

Managing Partner, Pappas Ventures

Art has over 30 years of operating experience as a pharmaceutical and biotechnology industry executive, and venture capital investor in life science companies. Art founded Pappas Capital in 1994, and over the past twenty-four years the firm has managed more than $540 million in capital and invested in more than 75 life science companies through its flagship Pappas Ventures business unit, as well as its Specialized Fund Management business unit.

Art currently serves as a director for Arix Bioscience, Aura Biosciences and OrphoMed, and as a board observer for Amplyx Pharmaceuticals, Balance Therapeutics, CuraSen Therapeutics, Kezar Life Sciences and Real Endpoints. Prior to founding Pappas Capital, Art held senior level leadership positions at several multinational pharmaceutical companies for which he was responsible for the development, licensing and launch of a number of global products. He was an executive member of the board of directors of Glaxo Holdings plc (NYSE: GLX, now GSK), and served as Glaxo’s chief executive responsible for international operations including research, development and manufacturing. Prior to Glaxo, Art was Vice President of Commercial Operations for Abbott International, and he held various executive and general management positions with Merrell Dow Pharmaceuticals and the Dow Chemical Company, in the United States and internationally. He previously served as Chairman and founding CEO of CoLucid Pharmaceuticals (NASDAQ: CLCD) (acquired by Eli Lilly in 2017), and on the boards of Afferent Pharmaceuticals (acquired by Merck in 2016), Chimerix (NASDAQ: CMRX), Quintiles Transnational Corp. (NASDAQ: QTRN now NYSE: Q), TYRX (acquired by Medtronic in 2013), Syntonix Pharmaceuticals (acquired by Biogen IDEC in 2007), LEAD Therapeutics (acquired by BioMarin in 2010), CardioDx, and Embrex (NASDAQ: EMBX) (acquired by Pfizer in 2006). He also served as a board observer for Plexxikon, which was sold to Daiichi Sankyo in 2011.

Art is a member of the Board of Directors of the North Carolina Biotechnology Center, where he was a past chair, and the Medical University of South Carolina Foundation for Research Development. He is a member of the Board of Trustees of The Wistar Institute (a National Cancer Institute center), the Board of Advisors of the Duke Cancer Institute, and the Advisory Board of the BioExec Institute. He is also a member of the CEO Roundtable on Cancer and BayHelix, an organization of global life science community leaders. He previously served on the Board of Directors of the National Venture Capital Association. Art is a decorated Vietnam veteran, having served as an officer in the US Army 101st Airborne Division and 2nd PSYOP Airborne Group JFK Special Warfare Center.

Ohio State University (BS in Biology)
Xavier University (MBA in Finance)


Marc Paradis

Vice President and Dean, Data Science University, Optum Labs

Marc is the Vice President and Dean of Data Science University (DSU). Marc joined Optum in July 2016 to help found, run and grow DSU. Within those 2 years DSU has grown from 12 unique students to over 1,200 unique global participants across multiple programs and colleges.

He is the principle lecturer and content developer across DSU’s Immersion College, Executive College, Mini-College and Data Science Academy. DSU’s vision is to transform the analytical DNA of Optum, UnitedHealth Care and UnitedHealth Group to be more data-centric, more data-savvy and more data-driven in support of our corporate mission to help people live healthier lives and to help make the health system work better for everyone.

Marc has a Master of Science degree in Brain and Cognitive Science from the Massachusetts Institute of Technology and a Bachelor of Science degree in Chemistry from Cornell University. He has been leading data science, advanced analytics, data warehousing and business intelligence teams and projects in the provider, payer, pharma, patient, academic and commercial spaces for over 18 years.


N. German Pasteris, PhD

Global Marketing Director, GlaxoSmithKline

German Pasteris is currently a global commercial leader within the Respiratory Franchise at GlaxoSmithKline (GSK). He has single commercial accountability for an asset in late stage development for asthma, COPD, bronchiectasis and other rare disease indications.

German has over nineteen years of industry experience (BMS, GSK) spanning global and US commercial roles across multiple therapeutic areas. He has led several programs across the product lifecycle, from commit to medicine development (Phase 2) through launch and patent expiration. During the past eight years, German has led development and commercialization programs in Alzheimer’s Disease, Multiple Sclerosis, Diabetes and Respiratory. German is a strategic thinker with a unique blend of scientific, clinical and business acumen on a mission to make an impact enhancing the lives of patients.

German has a Bachelor of Arts degree in Biology from the University of Pennsylvania, as well as a Doctorate in Human Genetics and a Masters in Business Administration from the University of Michigan.


Jim Pirouz

Managing Director, Head of Healthcare Investment Banking, SunTrust Robinson Humphrey

Panelist - Healthcare Consolidation

Jim joined SunTrust Robinson Humphrey in 2009 as a Managing Director covering Managed Care, Benefits Management and For-Profit Acute Care.

Since 2014, Jim has led the Healthcare Investment Banking Group including its expansion into Life Sciences and MedTech & Devices.

Previously a Director in Bank of America Merrill Lynch’s Leveraged Finance Group focusing on Healthcare and Financial Sponsor transactions.

Other experience includes Shearson Lehman Brothers/Smith Barney.

MBA from the University of North Carolina at Chapel Hill and BS from Cornell University.


Dr. Rhonda L. Randall, D.O.

Chief Medical Officer, UnitedHealthCare National Markets

As Chief Medical Officer of UnitedHealthcare National Markets, Rhonda Randall, D.O. collaborates with large group employers across the United States to deliver quality, cost-effective, long-term solutions for their employee and retiree health benefits.

She also leads the clinical strategy development for this business to improve quality outcomes, ensure affordability and improve health and well-being. Additionally, Dr. Randall supports the clinical strategy for UnitedHealth Group through her work in the corporate office of Medical Affairs and as a senior advisor to the UnitedHealth Foundation.

Since 2003, she has held clinical leadership roles in many UnitedHealth Group businesses, including: care delivery, Medicaid Long-Term Care, Medicare Special Needs Plans and Medicare Supplement. Following the 2003 passage of the Medicare Modernization Act that created the Medicare Part D prescription drug program, Dr. Randall was instrumental in developing UnitedHealthcare’s first Part D plans. In 2008, Dr. Randall transitioned to UnitedHealthcare Medicare & Retirement, serving first as regional chief medical officer for the Northeast, later concurrently as vice president and national medical director of medical management, as well as the deputy chief medical officer of Evercare Hospice and Palliative Care. From 2010 to 2013 she served as Chief Medical Officer for Medicare & Retirement and then as Chief Medical Officer for UnitedHealthcare Retiree Solutions. Dr. Randall’s leadership enabled the business to deliver unmatched clinical quality, facilitating market leadership in Group Medicare Advantage and achieving impressive 4.5 Star ratings for UnitedHealthcare’s national Group PPO plans.

Dr. Randall is a fellowship-trained geriatrician and is board certified in family practice. Her background includes years of practice in hospice and palliative medicine. Dr. Randall earned a bachelor’s degree in biology from Saint Vincent College in Latrobe, PA, and was honored in 2011 as one of the college’s Alumni of Distinction. She earned her medical degree from the Philadelphia College of Osteopathic Medicine. Dr. Randall completed her internship, residency, chief residency and fellowship at Florida Hospital in Orlando. She has served as volunteer clinical faculty in geriatrics for Florida Hospital’s Residency program and Florida State University College of Medicine. Dr. Randall has published papers on stroke, Alzheimer’s disease, polypharmacy and normal pressure hydrocephalus. She has also served on the First Coast Carrier Advisory Committee for Medicare Local Coverage Determinations. She is a two-time recipient of UnitedHealthcare’s innovation awards, some of the business’ highest honors, first in 2005 for her leadership in disaster planning and again in 2006 for her contribution to a clinical work group that developed a new model of care for people with advanced illness and end-of-life needs. She has been a champion for Florida’s frail elders in the public policy arena, working with policymakers to expand long-term care home and community-based services. She has also collaborated with state agencies to update regulations enabling seniors who are eligible for both Medicare and Medicaid can receive hospice services from the comfort of their homes instead of a nursing home. She is a member of the Florida Coalition on Physicians Orders for Life-Sustaining Treatment, as well as the national Coalition to Transform Advanced Care.

In addition to being actively involved in several national professional organizations, Dr. Randall currently serves as President of the Florida Medical Directors Association and a member of the house of delegate as well as the nominating committee for the American Medical Director’s Association. She is also Chair of the Board for St. Charles Borromeo Catholic School in Orlando, FL.


Markus Saba

Executive Director, Center for the Business of Health; Professor of the Practice, UNC Kenan-Flagler Business School

Markus Saba is an experienced pharmaceutical senior executive with an expertise in global and health care marketing.

He teaches courses in global health care and brand management. He leads the full-time MBA Program Health Care Concentration and serves as executive director of the Center for the Business of Health at UNC Kenan-Flagler.

Professor Saba also serves as a faculty advisor for Student Teams Achieving Results (STAR), a member of the Business School Alliance of Health Management, and the UNC Kenan-Flagler liaison to the Office of Interprofessional Education and Practice at Carolina.

During his 25-year career with Eli Lilly and Company, he held numerous marketing leadership positions. He led the global marketing efforts for diabetes business unit and neuroscience franchise at the company’s worldwide headquarters in Indianapolis, Indiana.

He launched and held global responsibility for some of the pharmaceutical industries’ best-known brands such as Prozac, Cymbalta, Zyprexa, Cialis, Humalog and Trulicity. He had geographic responsibility for Africa, Asia, Japan and the Middle East, and lived and worked in Dubai, Geneva, Kobe, Hong Kong, Philadelphia and Indianapolis.

He serves as an executive board member for Easter Seals Crossroads, a nationwide nonprofit helping people with disabilities.

He received his MBA from UNC Kenan-Flagler and his BS in marketing from Penn State University.


Jean B. Sellers, RN, MSN

Clinical Administrative Director, UNC Lineberger Comprehensive Cancer Center

Jean Sellers has led the development of patient navigation models at the statewide level for UNC Lineberger Comprehensive Cancer Center since 2007. Today, she consults with cancer centers and hospitals across North Carolina identifying cost effective measures for quality cancer care.

She earned her undergraduate degree in nursing and her master’s degree in nursing administration from UNC Greensboro. She is an adjunct faculty member of the UNC School of Nursing.

Sellers brings nearly 25 years of experience working in a variety of leadership positions within cancer clinics, hospitals and hospice communities. She is an active member of the Oncology Nursing Society, a member of the National Patent and Family Advocate Foundation’s President’s Council, and co-founder and current president of the North Carolina Oncology Navigator Association. Sellers was recognized as one of North Carolina’s Great 100 Nurses in 2000, and received the North Carolina Nurses Association’s Harriot Flint Oncology Nurse of the Year in 2002. She was appointed to the NC Advisory Committee on Cancer Coordination and Control from 2004 -2010. In 2017, she received a $600,000 Duke Endowment grant to expand UNC Lineberger’s model of lay patient navigation to 11 cancer hospitals and centers across North Carolina.


Mark Shaefer, PharmD

Global Medical Lead, Cabotegravir, ViiV Healthcare

With over twenty years of HIV and antiviral pharmaceutical experience, Mark’s roots run deep in ViiV Healthcare. As one of the earliest members during ViiV’s formation as a company, Mark is a key resource and respected for his depth of experience in the group.

His intensive pharmaceutical experience is complemented by expertise in clinical pharmacy, academic teaching, and research. Following the arc of his career, it’s easy to appreciate Mark’s dedication to ensuring access to innovative HIV medicines.

Current Role: As current Global Medical Lead for Cabotegravir and Mature Products for ViiV, Mark spearheads the global medical strategy for launch readiness for cabotegravir. This includes gathering critical medical and payer feedback to assist in the investigational development and planned launch of cabotegravir as a two-drug long-acting antiretroviral HIV treatment, and of a single-drug formulation for pre-exposure HIV prophylaxis. As leader of the Mature Products group, Mark oversees medical and safety aspects of the mature antiretroviral portfolio.

Experience: Mark’s pharmaceutical career in HIV and viral research follows a path of progressive responsibilities from Burroughs Wellcome where he worked on acyclovir and valaciclovir to Glaxo Wellcome, where he oversaw HIV clinical trials, and to GSK, where his expertise over the next nine years led him to more senior roles including Group Director and Acting Vice President. At GSK, Mark facilitated merger integration activities and later, as Acting Vice President, he led the US HIV program, co-chaired the US Commercial Strategy team, and represented HIV interests on the North American Medical Executive team. When Mark left GSK to join ViiV Healthcare during its founding in 2009, he was a natural choice for one of ViiV’s three Medical Affairs Heads. More recently, he progressed to his current position as Global Medical Lead for Cabotegravir and Mature Products.

Education: After completing an undergraduate degree in Biology from the University of California at San Diego, Mark earned his PharmD in 1985 from University of California at San Francisco followed by a Clinical Pharmacy Residency at the University of Nebraska Medical Center. Mark has held academic appointments as Assistant and Associate Professor at the University of Nebraska, is widely published with more than 60 peer-reviewed publications, and is valued as a reviewer for multiple pharmacy journals.

Personal Interests: Mark lives with his wife, Kristy, in Cary, NC, where they raised three children who are now successfully pursuing their own careers. As “empty-nesters”, Mark and Kristy are enjoying greater time and freedom to travel and participate in local events, including concerts, theater productions, Durham Bulls baseball games, and NC State football. Active in cycling and weight lifting, Mark enjoys helping Kristy with her sports photography business.


Christy Shaffer, Ph.D.

General Partner, Hatteras Venture Partners

Seasoned entrepreneur and biotech executive, Christy Shaffer, Ph.D. has over 25 years of experience in the life science industry. Following her career as a clinical scientist, international project leader and Associate Director of Pulmonary and Critical Care Medicine at Burroughs Wellcome Co., she joined Inspire Pharmaceuticals in 1995 as the first, full-time employee.

She was responsible for raising over $300m for the company, including taking the company public in 2000. As President and CEO, Christy grew the company from 20 scientists to nearly 250 employees with revenues of over $100 million. Under her leadership, Inspire was named as “Best Place to Work for Scientists” by the Scientist magazine, and “Best Place to Work in North Carolina.” Christy retired from Inspire in 2010 and the company was acquired by Merck in 2011. She joined Hatteras in 2011 as the Managing Director of Hatteras Discovery and became a general partner in 2016.

Christy serves as a board member of seven Hatteras portfolio companies and chairs five of them: Artizan Biosciences (Chair), Clearside Biomedical (Chair), GrayBug Vision (Chair), Trefoil Therapeutics (Chair), Kinodyn (Chair), G1 Therapeutics and Spyryx. Christy is a receptor pharmacologist by training, earning her Ph.D. in Pharmacology from the University of Tennessee Health Science Center, Memphis TN in 1985. She received her post-doctoral training at The Chicago Medical School and the University of North Carolina at Chapel Hill.

Community and Board Engagements:

Christy played an integral role in the Chancellor’s Innovation Circle to enhance entrepreneurship and innovation across the UNC-Chapel Hill campus (2010 – 2012). She has served on numerous boards including the NC Biotechnology Center, the Biotechnology Institute, BIO, PhRMA and the Cystic Fibrosis Foundation. Christy received the Breath of Life Award for the Cystic Fibrosis Foundation in 2009 and the Hamner Leadership Award at the NC BIOTECH meeting in 2011. TiE Atlanta awarded Christy the 2013 Venture Capital Entrepreneur Award at the TieCON Southeast conference.

She received the Lifetime Women in Business Award by the Triangle Business Journal in 2016 and was named one of the top BizWomen to Watch in December, 2016. Christy currently serves on several non-profit boards including the Chordoma Foundation, the Council for Entrepreneurial Development, the NC School of Science and Mathematics Foundation board, the Burroughs Wellcome Regulatory Initiative Advisory board, the Morehead Planetarium and Science Center Advisory board (Chair) and the Frank Hawkins Kenan’s Institute’s Advisory Board.


Pam Silberman, JD, DrPH

Professor and Director of the Executive Doctoral Program in Health Leadership, UNC Gillings School of Public Health

Pam Silberman, JD, DrPH, teaches courses on the health care system, services for underserved populations and the Affordable Care Act (ACA), and the health policy process. Her research interests focus on Medicaid, the health care safety net, the uninsured, rural health, and the ACA.

In 2014, Pam stepped down as president and CEO of the North Carolina Institute of Medicine (NCIOM). She served in this position from 2005-2014, and as vice president from 1999-2005. In her roles at the NCIOM she had a hand in shaping many state policies related to health care. Issues she addressed included rural health, state ACA implementation, the health care safety net, patient and family engagement, military health, the professional workforce, behavioral health, developmental disabilities, long-term care, dental care access, and health literacy. She has also done extensive work on promoting population health, helping to lead task forces that developed the North Carolina Prevention Action Plan, the Healthy NC 2020 objectives, and a plan to help local health departments in selecting, implementing, and evaluating evidence-based strategies to improve population health. She has received a number of awards for her work and has co-authored key publications in the field.

Dr. Silberman graduated with a doctorate in public health from the UNC School of Public Health in December in 1997. She obtained her law degree from the University of North Carolina at Chapel Hill in 1981, and her bachelor’s degree in political science and psychology from the University of Illinois, Urbana in 1977.


Liz Snyder

Executive Director, Ronald McDonald House of Chapel Hill, NC

Elizabeth currently serves as the Executive Director of the Ronald McDonald House of Chapel Hill, NC. Since 1974, Ronald McDonald House Charities have created programs that strengthen families during difficult times. The RMHC network of over 360 locations worldwide provide vital resources and compassionate care to children and their families being served by leading hospitals worldwide. Core RMHC programs — Ronald McDonald Houses, Ronald McDonald Family Rooms, and Ronald McDonald Care Mobiles — provide access to healthcare and enable family-centered care. RMHC helped lessen the burden for millions of families in 2017.

Prior to joining RMH in 2017, Elizabeth’s experience includes senior leadership roles for hospital-based or owned organizations that provide post-acute care services including Home Health, Hospice, Home Infusion and other post-acute care product lines. Elizabeth has assisted in the development and implementation of multi-discipline transitional care programs across senior and pediatric patient populations.

Elizabeth received her undergraduate degree from Drury University and received her Executive Masters in Healthcare Administration from Missouri State University.


Dr. Artie Southam, MD

Executive Vice President, Health Plan Operations, Kaiser Foundation Health Plan and Kaiser Foundation Hospitals

Arthur M. Southam, MD, is executive vice president, Health Plan Operations, for Kaiser Foundation Health Plan, Inc., and Kaiser Foundation Hospitals −− known as Kaiser Permanente, America’s largest not-for-profit, integrated health care system, Kaiser Permanente serves 12.2 million members and provides over $70 billion per year in health services in eight states and the District of Columbia. Dr. Southam joined Kaiser Permanente in 2001 and has national responsibility for Health Plan marketing, sales, service, and administrative activities that support growth, care and service. He is dedicated to helping Kaiser Permanente deliver high quality, affordable health care and coverage to more Americans.

Before joining Kaiser Permanente, Dr. Southam was chief executive officer of two California-based health plans, Health Net and CareAmerica.

In addition to his leadership responsibilities with Kaiser Permanente, Dr. Southam serves as Chairman of the Board for CHRISTUS Health, an international Catholic health system. He is a member of the Board of the Council for Affordable Quality Healthcare, a non-profit alliance that helps streamline health care administration, and he is a member of the Board of Advisors of the Fielding School of Public Health at UCLA. He served as a member of the Institute of Medicine’s Committee on the Quality of Health Care in America, contributing to the widely cited publications, To Err is Human and Crossing the Quality Chasm. He is a past chairman of the California Association of Health Plans.

Dr. Southam received his medical degree and Masters in Public Health from UCLA, and his MBA from Pepperdine University. He received his BA in Neuroscience from Amherst College.



UNC Kenan-Flagler Healthcare Club

The UNC Kenan-Flagler Healthcare Club is a student-run organization with a mission is to give MBA students pursuing a variety of functional roles the education, networking opportunities and job-finding skills they need to succeed in the healthcare industry.


The UNC Business of Healthcare Initiative

The UNC Business of Healthcare Initiative brings together schools across UNC to generate value in the practice of healthcare, prepare students for transformational careers in healthcare, create influential scholarship, and differentiate UNC by addressing a critical societal need.


Frank Hawkins Kenan Institute of Private Enterprise

The Frank Hawkins Kenan Institute of Private Enterprise is a nonpartisan business policy think tank affiliated with the University of North Carolina Kenan-Flagler Business School. Founded in 1985, the nonprofit institute facilitates collaboration between the private, public and nonprofit sectors to build a greater understanding of how entrepreneurship, economic development and global commerce can work for the public good. It leverages best-in-class research to develop market-based solutions to today’s most complex economic challenges; in doing so, the Kenan Institute aims to better the lives of people in North Carolina, across the country and around the world.

A Frank Hawkins Kenan Institute of Private Enterprise Event